Pharmaceutical Technology
Celltrion USA Signs Agreement With Express Scripts For Its Therapy For Autoimmune Diseases Including The First FDA-Approved Subcutaneous Infliximab ZYMFENTRA
Share
JERSEY CITY, N.J., April 28, 2024 /PRNewswire/ -- Celltrion USA announced today that it has signed an agreement with Express Scripts, one of the nation's leading pharmacy benefit managers (PBMs) negotiating on behalf of health plans covering more than 100 million people. The agreement, effective April 4, 2024 provides ZYMFENTRA Preferred Brand Access on the Express Scripts National Preferred Formulary serving 21.9 Million insured lives. Express Scripts provides plan participants such as Health Plans of the PBM the ability to add ZYMFENTRA™ (infliximab-dyyb) to their formularies.
"This agreement opens up an important pathway for access to treatment for millions of patients with chronic diseases," said Francine Galante, Vice President of Market Access at Celltrion USA. "We will continue to work with providers, patients and physicians to build upon our mission of developing transformational therapies that meet the needs of our patients living with chronic debilitating pain."
Celltrion's ZYMFENTRA, the first and only FDA-approved subcutaneous infliximab is now commercially available in the U.S.
The company continues to engage with national and regional health plans, as well as Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs), to communicate the value of its FDA-approved therapies including ZYMFENTRA for patients with autoimmune disease and to secure broad coverage.
About Celltrion USA
Celltrion USA is Celltrion's U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion currently has five biosimilars approved by the U.S. FDA: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), and YUFLYMA®(adalimumab-aaty) as well as a new biologic ZYMFENTRA™. Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence, and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit: www.celltrionusa.com/.
About ZYMFENTRA™ (infliximab-dyyb)[1]
ZYMFENTRA is a prescription medicine used as an injection under the skin (subcutaneous injection) by adults for the maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product given by intravenous infusion (IV), moderately to severely active Crohn's disease following treatment with an infliximab product given by intravenous infusion (IV). ZYMFENTRA blocks the action of tumor necrosis factor-alpha (TNF-alpha), a protein that can be overproduced in response to certain diseases and cause the immune system to attack normal, healthy parts of the body.
ZYMFENTRA™ (infliximab-dyyb) was approved by the FDA through the Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act (a "stand-alone" BLA). ZYMFENTRA is considered a new biologic with a first-approved subcutaneous administration form and thus will be under patent protection for its dosage form by 2037 and for its route of administration by 2040.
|
[1] Zymfentra Prescribing Information |
Contacts
Sarah Amundsen
samundsen@apcoworldwide.com
+1 920-946-0918
View original content to download multimedia:https://www.prnewswire.com/news-releases/celltrion-usa-signs-agreement-with-express-scripts-for-its-therapy-for-autoimmune-diseases-including-the-first-fda-approved-subcutaneous-infliximab-zymfentra-302129482.html
SOURCE Celltrion USA
First published on Mon, Apr 29, 2024
Enjoyed what you've read so far? Great news - there's more to explore!
Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.
Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.
Dive into TechDogs' treasure trove today and Know Your World of technology!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Trending PR Newswire
Propelr Named One Of 2025'S Best Enterprise LMS Platforms By Talented Learning
24 Exchange Appoints Gina Tuccio As Chief Financial Officer
Cyble And Botswana Communications Regulatory Authority (BOCRA) Sign Mou To Advance National Cybersecurity In Botswana
HOPPR Introduces Its AI Foundry: A Scalable, Secure Platform Accelerating The Development Of AI In Medical Imaging
Kia's All-Electric PV5 Secures Industry's Most Prestigious LCV Award
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion